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INTRO
T he extensive coverage of the worldwide !nancial crises has masked a looming crisis in healthcare. In addition to the 
financial constraints affecting every part of 
society, healthcare also faces an innovation 
crisis. Innovation in the field is clearly ad-
vancing faster than the ability of the system 
to adapt to the new innovations. Most experts 
acknowledge that the future of healthcare will 
involve sophisticated diagnostic and evalua-
tive processes to dictate precise approaches for 
the treatment of disease or the maintenance of 
individual health. The evidence in favour of 
personalised healthcare is accumulating rapidly 
in some areas – for example, the molecular diag-
nosis of cancer – but numerous barriers to rapid 
implementation remain. Because many of these 
new processes could save lives, we need to ask 
why rapidly expanding these new innovations 
to all patients is proving so dif!cult. 
A recent meeting in Luxembourg entitled 
“Personalized Medicine in Europe: What will 
it take to succeed?” brought together leaders 
from healthcare, business and academia to dis-
cuss the various aspects of implementation of 
personalized care. Unique and major challeng-
es face each sector of the system. Patients are 
faced with a bewildering spectrum of options; 
device and pharmaceutical manufacturers are 
faced with shrinking markets for each inter-
vention, making if dif!cult to create a pro!ta-
ble model. Physicians and health professionals 
face a big challenge in !ltering patient data to 
!nd the best, individualized intervention. Final-
ly, health policy experts are expressing concern 
about the cost of personalized medicine and the 
feasibility of introducing the new innovations 
without bankrupting the health system. 
Most developed countries now spend from 
8-12 % of GDP on healthcare, and feel that if 
this increases substantially, it will seriously 
affect other essential services and compromise 
overall quality of life. Thus, the radical changes 
required in healthcare systems to accommodate 
innovation must occur primarily by replacing 
old processes with new. This approach has failed 
in the past, as healthcare professionals are of-
ten reluctant to give up traditional approaches 
for new ones without overwhelming evidence 
of improved outcome and ef!ciency. 
Health policy experts know that introducing 
new processes from carefully controlled clinical 
trials into wide-spread clinical use almost nev-
er achieves the same ef!cacy as that obtained in 
the clinical study. Many factors account for this 
discrepancy, and these factors lead to a reluc-
tance to introduce expensive new processes that 
may not produce the expected bene!ts. 
A lot of healthcare researchers now recognize 
that we need to create a new process for introduc-
ing innovation into a healthcare system. Follow-
ing con!rmation in a clinical study, many new 
interventions should next be tested in an actu-
al healthcare environment to determine wheth-
er or not the bene!ts of the new process can be 
easily achieved in a realistic healthcare setting. 
Such experiments in ‘real’ healthcare systems 
are dif!cult to organize and manage, but sever-
al countries are leading the way in testing inno-
vations in a real-world setting before attempting 
to introduce the innovation in the entire system 
(the Maimonides Project). Such experiments in 
community settings – involving only a few thou-
sand people – can provide essential information 
on the feasibility of implementing the innovation 
in the entire system. The Maimonides group of 
countries has already achieved some document-
ed successes in implementing cost-effective in-
novations that improve health and well-being. 
Hopefully, more countries will adopt this inter-
mediate method of testing innovation, and will 
share their experiences with others.  
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